Biobehavioral Measurement Core

摘要 生物行为测量核心(安娜·马斯兰，CL) 本项目的目标是阐明心血管疾病中年差异的神经生物学。 疾病(CVD)风险。主要结果存在于两大领域：(1)临床前血管疾病和功能障碍 (2)心脏代谢风险。次要结果是心血管事件、高血压和2型糖尿病。 所有项目(P‘s)假定心血管疾病风险的共同近端介体，包括健康行为(例如， 物质使用、习惯饮食、体力活动和睡眠)，以及自主神经的候选生物介体 控制、全身炎症、内皮和HPA轴功能，以及氧化应激。启用制服的步骤 数据收集和跨P的协同，核心B团队将收集、验证和监控共享计划 结果和中介者，将数据传输到核心C，并连续报告逐个主题的协议 遵守核心A。核心B还将监督所有生物行为措施的质量保证，提供 集中保存与纵向测试有关的生物标本，就以下问题提供咨询和教育 对所有P团队进行生物行为测量，并协助解释调查结果。对于纵向分析，所有 在T1获得的针对P的1-3目标的测量将在后续评估中重新获得，以及 将获得新的或扩展的测量，因为这对于捕获哨兵预报器是可行的和有利的， 影响心血管疾病风险的中介因素和结果。我们将收集被招募到P的1-3级的899人的数据。核心B是 由马斯兰博士领导，他是行为免疫实验室的主任，生物样本将在那里 经过处理和存储。她由一名核心医务主任和门诊科长协助。医学部 主任是一名医生，负责监督参与者报告的临床诊断和事件 作为参与者的安全监测和相关的风险缓解战略。不卧床的部门领导将 监督计划队列中通常获得的所有动态措施，包括生态 即刻评估日记数据、动态血压和活动描记数据。

ABSTRACT Biobehavioral Measurement Core (Anna Marsland, CL) The objective of this Program Project is to elucidate the neurobiology of midlife disparities in cardiovascular disease (CVD) risk. Primary outcomes lay in 2 broad domains: (1) preclinical vascular disease and dysfunction and (2) cardiometabolic risk. Secondary outcomes are incident CVD events, hypertension, and type 2 diabetes. All projects (P's) postulate common proximal mediators of CVD risk, including health behaviors (e.g., substance use, customary diet, physical activity, and sleep), as well as candidate biomediators of autonomic control, systemic inflammation, endothelial and HPA-axis function, and oxidative stress. To enable uniform data collection and synergy across Ps, the Core B team will collect, verify and monitor shared Program outcomes and mediators, transfer data to Core C, and continuously report subject-by-subject protocol adherence to Core A. Core B will also oversee the quality assurance of all biobehavioral measures, provide centralized storage of biological specimens relevant to longitudinal testing, offer consultation and education on biobehavioral measures to all P teams, and assist with interpreting findings. For longitudinal analyses, all measurements obtained at T1 that address the aims of P's 1-3 will be re-obtained at follow-up assessments, and new or expanded measurements will be obtained as is feasible and advantageous to capture sentinel predictors, mediators and outcomes impacting CVD risk. We will collect data on 899 people recruited to P's 1-3. Core B is led by Dr. Marsland, Director of the Behavioral Immunology Laboratory where biological samples will be processed and stored. She is assisted by a Core Medical Director and Ambulatory Division Leader. The Medical Director is a physician who will assume oversight of participant-reported clinical diagnoses and events, as well as participant safety monitoring and associated risk mitigation strategies. The Ambulatory Division Leader will provide oversight of all ambulatory measures commonly obtained in the Program cohorts, including ecological momentary assessment diary data, ambulatory blood pressure, and actigraphy data.